Сравнение

Amycretin vs. Maridebart Cafraglutide

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Amycretin	Maridebart Cafraglutide
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Amycretin

Полная запись →

Maridebart Cafraglutide

Полная запись →

Frequently asked questions

What is the difference between Amycretin and Maridebart Cafraglutide?: Amycretin is classified as "Метаболизм", while Maridebart Cafraglutide is classified as "Метаболизм". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or Maridebart Cafraglutide?: The highest available evidence level is "РКИ на людях" for Amycretin and "РКИ на людях" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and Maridebart Cafraglutide in Germany and the United States?: Германия: Amycretin — Не одобрено, Maridebart Cafraglutide — Не одобрено. США: Amycretin — Не одобрено, Maridebart Cafraglutide — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

Maridebart Cafraglutide

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between Amycretin and Maridebart Cafraglutide?

Amycretin is classified as "Метаболизм", while Maridebart Cafraglutide is classified as "Метаболизм". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or Maridebart Cafraglutide?

The highest available evidence level is "РКИ на людях" for Amycretin and "РКИ на людях" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and Maridebart Cafraglutide in Germany and the United States?

Германия: Amycretin — Не одобрено, Maridebart Cafraglutide — Не одобрено. США: Amycretin — Не одобрено, Maridebart Cafraglutide — Не одобрено. These are factual summaries with source and review date on the individual pages.